Induced Pluripotent Stem Cell-Derived Cardiomyocytes: A Versatile Tool for Arrhythmia Research

Induced pluripotent stem cells offer the possibility to generate patient-specific stem cell lines from individuals affected by inherited disorders. Cardiomyocytes differentiated from such patient-specific induced pluripotent stem cells lines have been used to study the pathophysiology of arrhythmogenic heart diseases, such as the long-QT syndrome or catecholaminergic polymorphic ventricular tachycardia. Testing for unwanted drug side effects or tailoring medical treatment to the specific needs of individual patients with arrhythmogenic disorders may become future applications of this emerging technology.

[1]  Ricardo Bolaños,et al.  QT interval prolongation: preclinical and clinical testing arrhythmogenesis in drugs and regulatory implications. , 2010, Current drug safety.

[2]  Fred H. Gage,et al.  Modelling schizophrenia using human induced pluripotent stem cells , 2011, Nature.

[3]  Xiaoxia Qi,et al.  Heart repair by reprogramming non-myocytes with cardiac transcription factors , 2012, Nature.

[4]  Ofer Binah,et al.  Cardiomyocytes generated from CPVTD307H patients are arrhythmogenic in response to β-adrenergic stimulation , 2012, Journal of cellular and molecular medicine.

[5]  Rene Spijker,et al.  Differentiation of Human Embryonic Stem Cells to Cardiomyocytes: Role of Coculture With Visceral Endoderm-Like Cells , 2003, Circulation.

[6]  G. Koh,et al.  Genetically selected cardiomyocytes from differentiating embronic stem cells form stable intracardiac grafts. , 1996, The Journal of clinical investigation.

[7]  Azra Fatima,et al.  In vitro Modeling of Ryanodine Receptor 2 Dysfunction Using Human Induced Pluripotent Stem Cells , 2011, Cellular Physiology and Biochemistry.

[8]  Guy Salama,et al.  Mouse models of long QT syndrome , 2007, The Journal of physiology.

[9]  R. Shanks,et al.  Anti-arrhythmic drugs , 2018, Reactions Weekly.

[10]  N. Wiener,et al.  The Role of Models in Science , 1945, Philosophy of Science.

[11]  A. Marian.  Modeling Human Disease Phenotype in Model Organisms , 2011 .

[12]  Jing Zhang,et al.  Direct differentiation of atrial and ventricular myocytes from human embryonic stem cells by alternating retinoid signals , 2011, Cell Research.

[13]  Lila R Collins,et al.  Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts , 2007, Nature Biotechnology.

[14]  D. Roden,et al.  Genetic susceptibility to acquired long QT syndrome: pharmacologic challenge in first-degree relatives. , 2005, Heart rhythm.

[15]  Wei-Zhong Zhu,et al.  Neuregulin/ErbB Signaling Regulates Cardiac Subtype Specification in Differentiating Human Embryonic Stem Cells , 2010, Circulation research.

[16]  V. Vedantham,et al.  Direct Reprogramming of Fibroblasts into Functional Cardiomyocytes by Defined Factors , 2010, Cell.

[17]  Jonathan A. Bernstein,et al.  Using iPS cells to investigate cardiac phenotypes in patients with Timothy Syndrome , 2011, Nature.

[18]  Katriina Aalto-Setälä,et al.  Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture , 2011, Disease Models & Mechanisms.

[19]  Karl-Ludwig Laugwitz,et al.  Patient-specific induced pluripotent stem-cell models for long-QT syndrome. , 2010, New England Journal of Medicine.

[20]  J. Thomson,et al.  Embryonic stem cell lines derived from human blastocysts. , 1998, Science.

[21]  L Gepstein,et al.  Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes. , 2001, The Journal of clinical investigation.

[22]  D. Tamborero,et al.  Gender differences in clinical manifestations of Brugada syndrome. , 2008, Journal of the American College of Cardiology.

[23]  Olga K Afanasiev,et al.  Endogenous Wnt/β-Catenin Signaling Is Required for Cardiac Differentiation in Human Embryonic Stem Cells , 2010, PloS one.

[24]  R. Stewart,et al.  Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells , 2011, Nature.

[25]  Kitai Kim,et al.  Generating pluripotent stem cells: Differential epigenetic changes during cellular reprogramming , 2012, FEBS letters.

[26]  L. Gepstein,et al.  Identification and selection of cardiomyocytes during human embryonic stem cell differentiation , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[27]  G. Keller,et al.  In vitro differentiation of embryonic stem cells. , 1995, Current opinion in cell biology.

[28]  M. Schuldiner,et al.  Modeling for Lesch‐Nyhan Disease by Gene Targeting in Human Embryonic Stem Cells , 2004, Stem cells.

[29]  Robert Passier,et al.  Increased Cardiomyocyte Differentiation from Human Embryonic Stem Cells in Serum‐Free Cultures , 2005, Stem cells.

[30]  Shulan Tian,et al.  Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells , 2007, Science.

[31]  Li Qian,et al.  In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes , 2011, Nature.

[32]  E. Kaufman.  Mechanisms and clinical management of inherited channelopathies: long QT syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia, and short QT syndrome. , 2009, Heart rhythm.

[33]  E. Sasaki,et al.  Nongenetic method for purifying stem cell–derived cardiomyocytes , 2010, Nature Methods.

[34]  S. Yamanaka,et al.  Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors , 2006, Cell.

[35]  Divya Rajamohan,et al.  Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation , 2011, European heart journal.

[36]  C. Mummery,et al.  Induced pluripotent stem cell derived cardiomyocytes as models for cardiac arrhythmias , 2012, Front. Physio..

[37]  B. Knollmann,et al.  Induced Pluripotent Stem Cell–Derived Cardiomyocytes: Boutique Science or Valuable Arrhythmia Model? , 2013, Circulation research.

[38]  Gordon Keller,et al.  SIRPA is a specific cell-surface marker for isolating cardiomyocytes derived from human pluripotent stem cells , 2011, Nature Biotechnology.

[39]  C. Mummery,et al.  Cardiomyocytes Derived From Pluripotent Stem Cells Recapitulate Electrophysiological Characteristics of an Overlap Syndrome of Cardiac Sodium Channel Disease , 2012, Circulation.

[40]  R. Hauer,et al.  Proposed diagnostic criteria for the Brugada syndrome: consensus report. , 2002, Circulation.

[41]  Christine L Mummery,et al.  Differentiation of human embryonic stem cells and induced pluripotent stem cells to cardiomyocytes: a methods overview. , 2012, Circulation research.

[42]  T. Ichisaka,et al.  Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors , 2007, Cell.

[43]  C. Mummery.  Sorting cardiomyocytes: a simple solution after all? , 2010, Nature Methods.

[44]  S. Wolfe,et al.  Timing of new black box warnings and withdrawals for prescription medications. , 2002, JAMA.

[45]  Kevin Lohan,et al.  It's only a model! , 2014 .

[46]  Wataru Shimizu,et al.  Brugada syndrome: report of the second consensus conference. , 2005, Heart rhythm.

[47]  Riitta Lahesmaa,et al.  Copy number variation and selection during reprogramming to pluripotency , 2011, Nature.

[48]  Hideki Uosaki,et al.  Induction and Enhancement of Cardiac Cell Differentiation from Mouse and Human Induced Pluripotent Stem Cells with Cyclosporin-A , 2011, PloS one.

[49]  E. Kirkness,et al.  Somatic coding mutations in human induced pluripotent stem cells , 2011, Nature.

[50]  M. Sanguinetti,et al.  A mechanistic link between an inherited and an acquird cardiac arrthytmia: HERG encodes the IKr potassium channel , 1995, Cell.

[51]  A. Marian.  Modeling human disease phenotype in model organisms: "It's only a model!". , 2011, Circulation research.

[52]  A. Colman,et al.  Highly enriched cardiomyocytes from human embryonic stem cells. , 2008, Cytotherapy.

[53]  Shinsuke Yuasa,et al.  Disease characterization using LQTS-specific induced pluripotent stem cells. , 2012, Cardiovascular research.

[54]  M. S. Kallos,et al.  Expansion and long‐term maintenance of induced pluripotent stem cells in stirred suspension bioreactors , 2012, Journal of tissue engineering and regenerative medicine.

[55]  Sean P. Palecek,et al.  Functional Cardiomyocytes Derived From Human Induced Pluripotent Stem Cells , 2009, Circulation research.

[56]  D. Kerr,et al.  Predictive biomarkers: a paradigm shift towards personalized cancer medicine , 2011, Nature Reviews Clinical Oncology.

[57]  Laura Iop,et al.  Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia , 2012, EMBO molecular medicine.

[58]  L. Goodman,et al.  The Pharmacological Basis of Therapeutics , 1941 .

[59]  Lior Gepstein,et al.  Modelling the long QT syndrome with induced pluripotent stem cells , 2011, Nature.

[60]  T. Ichisaka,et al.  Induction of Pluripotent Stem Cells From Adult Human Fibroblasts by Defined Factors , 2008 .

[61]  J. Nerbonne,et al.  Genetic Manipulation of Cardiac K+ Channel Function in Mice: What Have We Learned, and Where Do We Go From Here? , 2001, Circulation research.

[62]  Ronald A. Li,et al.  Translational potential of human embryonic and induced pluripotent stem cells for myocardial repair: Insights from experimental models , 2010, Thrombosis and Haemostasis.

[63]  Shinya Yamanaka,et al.  Efficient and Scalable Purification of Cardiomyocytes from Human Embryonic and Induced Pluripotent Stem Cells by VCAM1 Surface Expression , 2011, PloS one.

[64]  B. London,et al.  Cardiac Arrhythmias: From (Transgenic) Mice to Men , 2001, Journal of cardiovascular electrophysiology.